Atomoxetine (Strattera®), a potent and selective inhibitor of the presynaptic norepinephrine
transporter, is used clinically for the treatment of attention-deficit hyperactivity disorder (ADHD…

BACKGROUND: Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the
treatment of attention-deficit/hyperactivity disorder (ADHD), is metabolized through the …

The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the pharmacokinetics of
atomoxetine hydrochloride [(−)-N-methyl-γ-(2-methylphenoxy)benzenepropanamine …

Objective: The goal of this study was to evaluate the tolerability and effectiveness of the
experimental, noradrenergic specific reuptake inhibitor atomoxetine in the treatment of children …

Objective: Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder
in children, adolescents, and adults. This study was conducted, in part, to evaluate the …

Accumulating evidence indicates that selective antagonism of kappa opioid receptors may
provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, …

The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by
paroxetine on atomoxetine disposition in extensive metabolizers. This was a single‐blind, two‐…

The κ-opioid receptor (KOR) is thought to play an important therapeutic role in a wide range
of neuropsychiatric and substance abuse disorders, including alcohol dependence. …

The effect of AKI and modern continuous RRT (CRRT) methods on drug disposition (pharmacokinetics)
and response has been poorly studied. Pharmaceutical manufacturers have little …

Background and Objectives Atomoxetine is a treatment for attention‐deficit/hyperactivity
disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6). The pharmacokinetics …